Is There Still a Role for Endocrine Therapy Alone in HR+/HER2– Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies

BACKGROUND: Different studies suggest that fulvestrant 500 mg every 28 days (HD-FUL) could be an active treatment in HR+ advanced breast cancer (ABC) patients even treated with aromatase inhibitors in the adjuvant setting. The aim of this analysis is to describe the outcome of ABC patients treated w...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Breast Care (Basel)
Main Authors: Cazzaniga, Marina Elena, Verusio, Claudio, Ciccarese, Mariangela, Fumagalli, Alberto, Sartori, Donata, Valerio, Maria Rosaria, Airoldi, Mario, Moretti, Gabriella, Ficorella, Corrado, Gianni, Lorenzo, Michelotti, Andrea, Zambelli, Alberto, Febbraro, Antonio, Generali, Daniele, Pistelli, Mirco, Garrone, Ornella, Musolino, Antonino, Vici, Patrizia, Maur, Michela, Mentuccia, Lucia, La Verde, Nicla, Bianchi, Giulia Valeria, Artale, Salvatore, Blasi, Livio, De Laurentiis, Michelino, Atzori, Francesco, Turletti, Anna, Porpiglia, Mauro, Santini, Daniele, Fabi, Alessandra, Gebbia, Vittorio, Schirone, Alessio, Palumbo, Raffaella, Ferzi, Antonella, Frassoldati, Antonio, Scavelli, Claudio, Clivio, Luca, Giordano, Monica, Donadio, Michela, Biganzoli, Laura, Del Mastro, Lucia, Bisagni, Giancarlo, Livi, Lorenzo, Natoli, Clara, Montemurro, Filippo, Riccardi, Ferdinando, Romagnoli, Emanuela, Marchetti, Paolo, Torri, Valter, Pronzato, Paolo, Mustacchi, Giorgio
Formato: Artigo
Idioma:Inglês
Publicado: S. Karger AG 2020
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7098305/
https://ncbi.nlm.nih.gov/pubmed/32231495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000495469
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares